RapidAI announced today that it received FDA 510(k) clearance for its Rapid PE Triage & Notification product.
San Mateo, California-based RapidAI designed its Rapid PE Triage & Notification product for the fast identification and communication of suspected central pulmonary embolism (PE).
According to a news release, Rapid PE Triage & Notification works in conjunction with RapidAI’s Rapid Workflow for PE offering. Rapid Workflow for PE, which the company designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism, was launched in June 2021.
The company said its newly cleared platform will enable care teams to more easily manage the entire patient care journey from the moment a suspected PE patient is identified to diagnosis and through treatment. Patients can be triaged faster and care teams can be aligned more quickly to reduce the overall time to treatment thanks to the automatic identification of a suspected pulmonary embolism, plus real-time notifications.
“Building on our expertise in stroke, we’re confident this technology will help modernize PE care and meaningfully improve patient outcomes,” RapidAI CEO Karim Karti said in the release. “Our goal is to build solutions that address the specific challenges associated with treating various conditions, as well as the communication and workflow issues faced by hospitals globally. From stroke to aneurysm to PE, we’re proud of how much RapidAI has grown and are excited to continue to redefine the patient care journey.”
